Navigation Links
Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009
Date:2/2/2009

>Haemonetics reported balanced double digit revenue growth in all geographies year-to-date, with North American sales up 21%, European sales up 17%, Japanese sales up 11%, and Asian sales up 21%.

FISCAL 2009 GUIDANCE

The Company raised its annual revenue guidance to 15-16% growth (from 12-14% growth) on stronger than planned sales of plasma disposables, blood bank disposables, and equipment sales, with strong contribution from each of the geographies. Adjusted operating income is expected to grow 23-25%, and adjusted earnings per share are expected to be between $2.40 to $2.44, up 14-16%. The Company further expects gross margin improvement of 120 basis points, operating margin improvement of 120 basis points, and a tax rate of 32.5% in the year.

For the full year 2009, the Company expects to generate $40 million of free cash flow.

Haemonetics has refined its fiscal 2009 guidance and posted revised income scenarios reflecting guidance ranges as well as potential fiscal 2009 product line growth on its website at http://www.haemonetics.com/site/content/investor/guidance.asp.

As part of this release, Haemonetics has presented supplemental non-GAAP financial results which exclude restructuring costs in fiscal 2008 and fiscal 2009. Haemonetics believes that these non-GAAP results are useful to investors because it allows for an evaluation of the Company with a focus on the results of our core business.

CONFERENCE CALL

Haemonetics will host a webcast on Monday, February 2nd at 10:00 am Eastern to discuss these results. Interested parties can participate at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&am
'/>"/>

SOURCE Haemonetics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Haemonetics Webcast Presentation
2. Keiko Hattori Joins Haemonetics as President of Haemonetics Japan
3. Haemonetics Appoints Executive Leadership of European Operations
4. Haemonetics Sets Date for Q3FY08 Earnings Release and Conference Call - January 31, 2008
5. Haemonetics(R) Reports Strong Results for Third Quarter Fiscal 2008 with Continued Double Digit Growth in Sales
6. Haemonetics(R) Software Solutions to Launch Application for Workflow Optimization in Blood Collection Centers
7. Haemonetics Sets Date for Fourth Quarter and Fiscal Year End 2008 Earnings Release and Conference Call - May 1, 2008
8. Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009
9. Haemonetics Chairman and CEO Adopts 10b5-1 Stock Trading Plan
10. Haemonetics Sets Date for First Quarter Fiscal Year 2009 Earnings Release and Conference Call - August 1, 2008
11. Haemonetics Announces Promotion of Brian Concannon to CEO Effective April 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... 2014 The clinical trial report, ... data on the Aspergillosis clinical trial scenario. This ... the clinical trials on Aspergillosis. It includes an ... status as per the site of trial conduction ... coverage of disease clinical trials by their phase, ...
(Date:11/23/2014)... Tbdress.com has recently announced that its Special ... 2014. The special offer will provide ladies many gorgeous shoes ... the world’s largest women’s dresses retailers, and its shoes include ... great discounts on that day: Everything at Tbdress.com is up ... above $89). , People can use the following coupon codes ...
(Date:11/23/2014)... SUNDAY, Nov. 23, 2014 (HealthDay News) -- The holidays ... autism because sensory overload can trigger major meltdowns, an ... under the best of circumstances, but when you have ... Varleisha Gibbs, an occupational therapy professor at University of ... release. "It,s best to let your hosts or ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers ... has announced its new collection of power suppliers. Additionally, ... quality power suppliers. All the new models come with ... lasts until Dec. 20, 2014. , SWAccessControl.com has thousands ... supporting it for a long time. It is very ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 “BlackVue” was ... Tech Report , which features the latest and coolest ... expert and reporter for NewsWatch, conducted the product review ... unique and powerful options in the car camera industry. ... and it can be hard to find the one ...
Breaking Medicine News(10 mins):Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2
... ... ... ... ...
... ... ... ... ...
... ... ... , ... TULSA, Okla. , Feb. 19 U.S. ...
... more fumes that are likely carcinogenic than with electric ranges ... hot stove -- make that a hot gas ... cancer. , Researchers in Norway have found that cooking with ... , But, in a report published online Feb. 17 in ...
... (P4P) programs are payment models that reward workers for ... the healthcare setting, P4P programs use a variety of ... fee differentials and bonuses. A new study ... that P4P programs appear to be effective in incentivizing ...
... ... momentum created by local communities and the NGO Tostan to end the practice by 2015 ... Dakar, Senegal (PRWEB) February ... cutting (FGC) which has seen thousands of communities in Senegal join its ranks in recent ...
Cached Medicine News:Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 2Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 3Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 4Health News:Abbott Announces 10 Percent Increase in Quarterly Dividend 2Health News:Abbott Announces 10 Percent Increase in Quarterly Dividend 3Health News:Two Tulsa Pharmacies Penalized for Missing Prescription Drugs 2Health News:Two Tulsa Pharmacies Penalized for Missing Prescription Drugs 3Health News:Gas Cooking Might Up Your Cancer Risk 2Health News:Gas Cooking Might Up Your Cancer Risk 3Health News:Senegal: Total End of Female Genital Cutting Now in Sight 2
(Date:11/24/2014)... , Nov. 24, 2014 The Female Health ... an investor conference call to discuss its operating results ... 30, 2014 on Tuesday, December 2, 2014 at 11:00 ... report its operating results earlier the same day. ... the conference call by dialing 1-877-374-8416 (international participants dial ...
(Date:11/24/2014)... Nov. 24, 2014  GlySens Incorporated announced today that ... grant from the National Institute of Diabetes and Digestive ... Institutes of Health (NIH).  The grant is intended to ... ICGM™ long term implantable glucose monitoring system.  Final preparations ... is expected to begin before the end of 2014. ...
(Date:11/24/2014)... DEVON, England , Nov. 24, 2014 /PRNewswire/ ... https://www.facebook.com/PifflersUnited announced the release of results ... pain therapy device, in the self-management of fibromyalgia ... the area of worst pain, very significant clinically ... The 140 group members with fibromyalgia used ...
Breaking Medicine Technology:The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3
... today that eleven presentations or publications on pre-clinical and ... several major tumor types will be made during the ... May 29-June 2, in Orlando, Florida. Abstracts are ... http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ) Prostate Cancer ...
... (LSE: SHP, Nasdaq: SHPGY ), the global specialty ... of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII with the ... X 2), did not alter the median time it took ... reached in the subjects evaluated. In the same study, ...
Cached Medicine Technology:Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000) ...
Medicine Products: